Cue Biopharma, Inc. (CUE) vs Nkarta, Inc. (NKTX)
A side-by-side comparison of Cue Biopharma, Inc. and Nkarta, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CUE
Cue Biopharma, Inc.
$23.47HealthcareDelayed quote: Oct 6, 2026, 2:30 PM EDT
NKTX
Nkarta, Inc.
$2.34HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — CUE vs NKTX
growth of $100 · dividends reinvested · last 6yCUE -96.4% (-42.6%/yr)NKTX -94.7% (-38.7%/yr)NKTX compounded faster over this window
CUE NKTX
CUE vs NKTX: by the numbers
- •CUE is the larger company ($170M vs $167M market cap).
- •Both run net losses; NKTX's is the smaller (0.00% vs -435.83% net margin).
Metrics side by side
Valuation
| Metric | CUE | NKTX |
|---|---|---|
| P/S ratio | 4.53 | N/A |
| P/B ratio | 73.81 | 0.67 |
Profitability
| Metric | CUE | NKTX |
|---|---|---|
| Gross margin | 99.69% | 0.00% |
| Operating margin | -96.56% | 0.00% |
| Net margin | -435.83% | 0.00% |
| ROE | -7104.24% | -47.36% |
| ROIC | -1039.56% | -42.11% |
Growth (annualized)
| Metric | CUE | NKTX |
|---|---|---|
| Revenue CAGR (5Y) | 47.08% | N/A |
| Total return CAGR (5Y) | -42.42% | -37.28% |
Frequently asked
- How have CUE and NKTX total returns compared?
- Over the past 5 years, CUE delivered -42.42% and NKTX delivered -37.28% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cue Biopharma ROENkarta ROECue Biopharma operating marginNkarta operating marginCue Biopharma revenue growthNkarta revenue growthCue Biopharma free cash flowNkarta free cash flow
Cue Biopharma & Nkarta appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.